Last updated on March 2019

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL


Brief description of study

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Clinical Study Identifier: NCT02393157

Find a site near you

Start Over

New York Medical College

Valhalla, NY United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.